Abemaciclib, a cyclin-dependent kinase 4/6 (CDK4/6) inhibitor used for hormone-receptor-positive and human epidermal growth factor receptor 2 (HER-2)-negative breast cancer, can lead to elevated serum creatinine without implications on the true renal function. Although clinical trials have shown no increase in other kidney function biomarkers, this may still represent a challenge in cancer patients. We report a case of a 74-year-old female who presented with creatinine and cystatin-C elevation during treatment with abemaciclib without an equivalent decrease in measured glomerular filtration rate (GFR) with renal scintigraphy. The confirmation of adequate kidney function allowed for the maintenance of treatments that would otherwise be limited by renal impairment. Healthcare providers should be aware of abemaciclib's effect on serum creatinine but should not eliminate the possibility of actual kidney injury. Alternative biomarkers for GFR assessment are recommended, although the usefulness of cystatin-C in patients receiving abemaciclib should be investigated in greater depth.
Summary: Well interventions, especially in offshore wells, are costly and usually very time-consuming to conduct. This is related mainly to the need for a rig or a similar unit to perform these operations. In this paper we propose the development of an autonomous robot for rigless well interventions. The robot will be inserted through the tree using a special tool. This proposal will result in significant cost reduction by eliminating the rig when performing light–workover operations in offshore locations. This reduces intervention time because a simpler unit might be used to deploy the robot. Examples of operations that could be performed by the robot are production logging, gas–lift valve replacement, sliding–sleeve opening and closing, and plug insertion or removal. To evaluate this proposal, a conceptual robot was designed. The feasibility of this conceptual robot was evaluated theoretically. After that, a simplified test robot was constructed to test critical aspects experimentally, in laboratories, and in a test well. The traction system, energy storage, and a positioning algorithm were evaluated. In this paper we will outline the intervention strategy proposed, perform a theoretical evaluation of this proposal on the basis of the conceptual robot, and present experimental results obtained with the simplified test robot.
Acute kidney injury (AKI) is a frequent and severe complication in hospitalised cancer patients. However, overall data from in-hospital drug-related AKI in cancer patients is scarce. We aim to review the profile of moderate to severe drug-induced AKI in patients admitted to an oncology hospital over the last two decades and to assess renal and overall outcomes. 410 cases of drug-induced AKI KDIGO≥2 were analyzed, comparing between two decades from 2002 to 2021 in a comprehensive cancer center. The main differences were the introduction of new classes of cancer therapy (e.g., immune checkpoint inhibitors [ICPI] and tyrosine kinase inhibitors [TKI]), a decrease in nephrotoxicity due to platinum-based drugs, and an increase in nephrotoxicity caused by multiple drugs without cancer-directed therapy. Mortality was similar, but the need for haemodialysis (HD) was higher in the second decade (25.5% vs 36.6%, p=0.02). Multivariate analysis presented invasive mechanical ventilation and sepsis as risk factors for both HD and mortality, haematologic cancer as risk factors for HD, and the need for HD and multiple drugs without cancer-directed therapy as risk factors for mortality. Adequate drug surveillance and prophylaxis render cancer therapy as a relatively small contributor to drug-induced AKI in a comprehensive cancer center. Critically ill patients have a higher need for HD and mortality regardless of the nephrotoxic agent implied.
3 July 2023 in Portuguese Journal of Nephrology & Hypertension